Eli Lilly & Co. is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399 a month as it works to overcome supply shortages of wildly popular shots.
Eli Lilly & Co. is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399 a month as it works to overcome supply shortages of wildly popular shots. Eli Lilly & Co. is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399 a month as it works to overcome supply shortages of wildly popular shots.
The move is part of Lilly’s “all hands on deck” effort to ramp up supply of Zepbound and a similar drug for diabetes called Mounjaro amid widespread shortages, Executive Vice President Patrik Jonsson said in an interview. It also offers uninsured patients a cheaper option for weight-loss shots that can cost upwards of $1000 a month.
The vials’ price may also raise pressure on Novo. This is a lever that Novo can’t pull for its own drug for the time being because it has had difficulty making enough of the active ingredient in its drugs, semaglutide. For Lilly, the complexity of making its injector pens has bottlenecked supply. Earlier this year, patients struggling to fill their prescriptions began urging Lilly to sell the drug in easier-to-produce vials, as it does already in other countries. “They have that ripcord they could pull here to alleviate the shortages,” Dave Knapp, who started a social media campaign to pressure Lilly to #ReleaseTheVials, told Bloomberg News in April.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly slashes price of weight-loss drug Zepbound by 50% to sell in smaller dosesThe more affordable vials are marketed toward patients whose health insurance will not reimburse them for the cost of the drug.
Read more »
Eli Lilly cuts cost of certain Zepbound doses by at least 50%Eli Lilly is launching more supply of its weight loss drug Zepbound. The new single-dose vials will be priced lower than 'all other incretin GLP-1 medicines for obesity.'
Read more »
Eli Lilly releases discounted single-dose vials of Zepbound weight loss drugRooted in fact-based, transparent reporting, Newsy is an award-winning opinion-free network owned by the E.W. Scripps Company that is relentlessly focused on “the why” of every story and seeks to enable a more intimate and immersive understanding of the issues that matter.
Read more »
Eli Lilly slashes prices of weight-loss drug Zepbound for single-use vialsThe cheaper drug will compete with compounded versions of the same medication sold by digital health companies.
Read more »
Eli Lilly to sell Zepbound directly to consumers without insurance coverageEli Lilly is announcing a new way to get its popular Zepbound drug.
Read more »
Eli Lilly to sell Zepbound directly to consumers without insurance coverageEli Lilly is announcing a new way to get its popular Zepbound drug.
Read more »